ADCT
ADC Therapeutics S.A.$1.09
LiveJun 18, 2026
Market cap
$138.64M
52w range
0.78 – 4.98
P / E
—
EPS
—
Volume
771.51K
Revenue · FY
—
Explain this page
Arphra AIPlain-English read on ADC Therapeutics S.A.’s valuationNo recent stories.
today
- ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)14d
- ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Data17d
- ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcript17d
- ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcript48d
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $3.50 (+221.10%)
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.80% | +0.93% | -67.94% | -71.76% | -70.78% | -69.12% | -59.33% | -50.00% | -95.70% | -96.32% | -96.32% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$1.11
Bid
$1.00
2,800 sh
Ask
$1.11
2,100 sh
Spread
$0.110
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- ADC Therapeutics Tumbles On Phase 3 Trial Safety Concerns, Joins Other Big Stocks Moving Lower In Thursday's Pre-Market Session (CORRECTED)feeds.benzinga.com·Jun 06, 2026
- ADCT Stock Plunges on Safety Concerns Despite Positive Lymphoma Datazacks.com·Jun 04, 2026
- ADC Therapeutics SA (ADCT) Discusses Phase III LOTIS-5 Trial Results and Next Steps in DLBCL Transcriptseekingalpha.com·Jun 03, 2026
- ADC Therapeutics SA (ADCT) Q1 2026 Earnings Call Transcriptseekingalpha.com·May 04, 2026
- ADC Therapeutics SA (ADCT) Reports Q1 Loss, Beats Revenue Estimateszacks.com·May 04, 2026
- Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?zacks.com·May 01, 2026
Recent analyst activity
DB- Jun 08, 2026GradeBuy → NeutralADC Therapeutics downgraded to Neutral from Buy at H.C. WainwrightH.C. Wainwright
- Jun 04, 2026GradeOverweight → OverweightADC Therapeutics price target lowered to $5 from $8 at StephensStephens
- Jun 04, 2026PT$5.00ADC Therapeutics price target lowered to $5 from $8 at StephensStephens
- Jun 04, 2026GradeOverweight → OverweightADC Therapeutics (ADCT) Reiterated at Overweight by Cantor FitzgeraldCantor Fitzgerald
- Jun 04, 2026GradeOutperform → Sector PerformADC Therapeutics downgraded to Sector Perform from Outperform at RBC CapitalRBC Capital
- Jun 04, 2026PT$2.00ADC Therapeutics downgraded to Sector Perform from Outperform at RBC CapitalRBC Capital
Peers
No peer list available for ADCT.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|